Hereditary Hepatorenal Tyrosinemia Natural History in Egypt and the Arab World (Multicenter Clinical Study)

Hereditary Tyrosinemia, Type I Clinical Trial

Official title:
Hereditary Hepatorenal Tyrosinemia Natural History (Multicenter Clinical Study): Registry for Patients With Tyrosinemia Type I in Egypt and the Arab World

Status Recruiting

Clinical Trial Summary

The purpose of the registry/repository is to understand the natural history of tyrosinemia in our region and to provide a mechanism to store data and specimens to support the conduct of future research about hereditary tyrosinemia among the Arabs.

Clinical Trial Description

The purpose of this study is to create an electronic registry of phenotypic, laboratory information, treatment and outcomes options for tyrosinemia type I. The registry is longitudinal in nature including retrospective clinical data from birth to the most recent encounter with all data entered in chronological fashion. The goals of this registry are the better understanding of the natural history and treatment outcomes of these patients and to determine/evaluate biochemical and clinical parameters for monitoring and prognosis of tyrosinemia type I. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03446586
Study type	Observational [Patient Registry]
Source	Yassin Abdelghaffar Charity Center for Liver Disease and Research
Contact	Mamdouh A. Ahmed
Phone	02-01221707770
Email	dr.yassinabdelghaffar@gmail.com
Status	Recruiting
Phase
Start date	April 5, 2019
Completion date	December 31, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02320084` - Long Term Safety Study of Orfadin Treatment in HT-1 Patients in Standard Clinical Care
Completed	`NCT02750709` - Bioequivalence Study of Two Nitisinone Formulations Compared to Orfadin	Phase 1
Completed	`NCT01734889` - Taste and Palatability of Orfadin Suspension	Phase 1
Completed	`NCT02750332` - Bioavailability Food-Effect Study of an Oral Nitisinone Formulation to Treat Hereditary Tyrosinemia (HT-1)	Phase 1
Not yet recruiting	`NCT04113772` - Bio Equivalency 20 Mgm Orfadin and 20 Mgm of Nitisonine	N/A
Completed	`NCT02750345` - Bioequivalence Study of Two Oral Nitisinone Formulations to Treat Hereditary Tyrosinemia (HT-1)	Phase 1
Completed	`NCT02323529` - Efficacy and Safety of Once Daily Dosing Compared to Twice Daily Dosing of Nitisinone in HT-1	Phase 3
Recruiting	`NCT06227429` - A Non-interventional, Post-Marketing Study to Describe Outcome of Nitisinone Treatment in HT-1 Patients